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We were sitting in the Irish pub on quiz night, dumb-
founded by trivia questions about ingredients of Mornay
sauce and best-selling Boy Bands, when the following
question came up: What are ‘Live microorganisms which
when administered in adequate amounts confer a health
benefit on the host?’At long last, we had a correct answer:
PROBIOTICS! The quizmaster was totally disinterested in
our extensive elaboration on this topic, so we offer it to the
readers of this Genomics Update.
The Russian Noble Prize winner Elie Metchinkoff first
suggested that certain bacteria could modify the compo-
sition of the gut flora (Metchnikoff, 1907). He suggested
that the longevity of Bulgarians and Russians of the
Steppes was due to their consumption of ‘sour milk’ con-
taining beneficial microbes, which in fact probably were
lactic acid bacteria (LAB) such as Lactobacillus bulgari-
cus. Henry Tissier of the Pasteur Institute isolated bacte-
ria (now called Bifidobacterium bifidum) from the faeces of
healthy breast-fed infants and recommended giving it to
babies suffering from diarrhoea (Tissier, 1900). In 1935,
Minoru Shirota in Japan developed the first commercial
probiotic drink called Yakult, which contains Lactobacillus
casei Shirota that can survive the passage through the
stomach and colonize the intestine. The probiotic market
is now estimated to be worth about $6 000 000 000 a year
and is growing at around 10% annually (UBIC-Consulting,
2008). Since 1981 there have been over 2000 patent
applications on probiotics filed (with ‘probiotic’ mentioned
in patent somewhere) and some 524 granted (in the USA
and Europe). The two most commonly used probiotics in
commercial products are lactobacilli, members of the
LAB, and bifidobacteria, but some yeasts and other
bacteria have been claimed to have probiotic potential.
See Table 1 and Ouwehand and colleagues (2002) for an
overview of commercially used strains and their claimed
probiotic effects.
Probiotic mechanisms
What do probiotics actually do? What is the meaning of
‘confer a health benefit’? Probiotics are most commonly
known as yoghurts or yoghurt-type drinks that people
ingest. The consumption of probiotics by humans is
intended to improve or maintain a healthy intestine. The
claimed modes of action of probiotics include strengthen-
ing of the intestinal barrier function, modulation of immune
responses, supply of vitamins, and antagonism of
pathogens (or other commensals) either by producing
antimicrobials or by binding to the mucosa (so called
competitive exclusion). (For recent reviews see Marco
et al., 2006; Ventura et al., 2007; Kalliomaki et al., 2008;
Lebeer et al., 2008; Kleerebezem and Vaughan, 2009.) In
general, desired attributes of probiotic strains include
adequate survival of the stomach passage (i.e. low pH
stability), and adaptation to the host gut environment,
including stress response, active and synergistic metabo-
lism, and adherence to the intestinal mucosa and mucus.
Probiotics are presumed to have an ecological advantage
owing to their capacity to metabolize complex sugars that
are derived from the diet as well as from the host. Sugar
metabolism enzymes include various glycosyl hydrolases
(GHs) which can degrade plant-derived dietary fibres or
complex host carbohydrate structures. Bacteriocin pro-
duction may enhance their competitiveness in the gut.
From an industrial perspective, crucial attributes of probi-
otic strains are good technological properties for produc-
tion and storage and low health risk to consumers.
Probiotics need not be restricted to food applications
or oral delivery. Some can be applied to the skin as
lotions or cream (Krutmann, 2009) and have been used
to treat vaginal infections (Reid, 2008). Probiotics are
also added to animal and fish feed to enhance growth,
replacing the banned additive antibiotics or growth hor-
mones (Gatesoupe, 2008; Higuchi et al., 2008; Wynn,
2009). They appear to work by inhibiting/reducing the
pathogenic bacterial load that some animals or fish
carry. There is evidence for all of these probiotic modes,
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but the exact mechanisms of action are still not very
clear. Genome-scale analyses of health-promoting
bacteria, also coined ‘probiogenomics’ (Ventura et al.,
2009), should provide clues for probiotic mechanisms
and potential. Here, we provide an update of recent
genomics studies in this field.
Genome sequencing
Table 2 and Fig. 1 give an overview of genome sequenc-
ing of putative probiotic bacteria that are publicly
available, and Table 3 gives examples of proprietary
sequences of commercial probiotics. By far the most
Table 1. Examples of commercial probiotic strains and products (adapted from http://en.wikipedia.org/wiki/Probiotic#cite_note-48).
Species/strain Brand name Producer Claimed effect in humans/animals
Bacillus coagulans GBI-30, 6086 GanedenBC30 Ganeden Biotech Improves abdominal pain and bloating in
IBS patients. Increases immune
response to viral challenge
Bifidobacterium animalis ssp. lactis
BB-12
BB-12 Chr. Hansen Reduction in Strept. mutans in mouth;
IBS amelioration in a multispecies trial
Bifidobacterium animalis ssp. lactis
HN019 (DR10)
Howaru Bifido Danisco Reduced prevalence of atopy and
eczema in the first 2 years of life
Bifidobacterium breve Yakult Bifiene Yakult Ulcerative colitis amelioration
Bifidobacterium infantis 35624 Align Procter & Gamble Irritable bowel syndrome treatment
Bifidobacterium longum BB536 BB536 Morinaga Treatment of allergy, especially
Japanese cedar pollinosis
Escherichia coli M-17 ProBactrix BioBalance Irritable bowel syndrome treatment
Escherichia coli Nissle 1917 Mutaflor Ardeypharm Enterocolitis, remission of ulcerative
colitis
Lactobacillus acidophilus DDS-1 DDS-1 Nebraska Cultures Alleviation of traveller’s diarrhoea;
vitamin production
Lactobacillus acidophilus LA-5 LA-5 Chr. Hansen Alleviation of acute diarrhoea
Lactobacillus acidophilus NCFM Howaru acidophilus Danisco Improvement of intestinal health,
treatment of vaginal/urogential
infections
Lactobacillus acidophilus GAL-2 Ghenisson 22 GHEN Co Improves digestive health in poultry
Lactobacillus brevis KB290 LABRE Kagome Improvement of bowel movement,
enhances NK activity and interferon-a
activity
Lactobacillus casei DN114-001 Actimel, DanActive Danone Acute diarrhoea treatment; infection
prevention; gut development
Lactobacillus casei CRL431 CRL431 Chr. Hansen Immune stimulation, Alleviation of acute
diarrhoea
Lactobacillus casei F19 Cultura Arla Foods Improvement in bowel function
Lactobacillus casei Shirota Yakult Yakult Alleviation of acute diarrhoea
Lactobacillus paracasei St11 Lactobacillus fortis Nestlé Natural defence/immune system, gut
health
Lactobacillus johnsonii NCC533 LC1 range Nestlé Immunomodulation; pathogen inhibition
Lactococcus lactis L1A VERUM HÄLSOFIL Norrmejerier Immune stimulation; improves digestive
health; reduces antibiotic-associated
diarrhoea
Lactobacillus plantarum 299v GoodBelly, ProViva, TuZen NextFoods, Probi, Ferring Iron absorption
Lactobacillus reuteri ATTC 55730 L. reuteri Protectis BioGaia Biologics Diarrhoea prevention and mitigation;
eradication of H. pylori infection;
amelioration of gingivitis.
Lactobacillus rhamnosus GG Vifit and others Valio Immune stimulation; alleviates atopic
eczema; prevents diarrhoea in
children and many other types of
diarrhoea
Lactobacillus rhamnosus LB21 Verum Norrmejerier
Lactobacillus rhamnosus GR-1 &
Lactobacillus reuteri RC-14
Bion, Flore, Intime, Jarrow,
Fem-Dophilu
Chr. Hansen Vaginal colonization and prevention of
vaginitis
Lactobacillus acidophilus NCFM &
Bifidobacterium bifidum BB-12
Florajen3 American Lifeline, Inc Reduction of C. difficile–associated
disease (CDAD)
Lactobacillus acidophilus CL1285 &
Lactobacillus casei
Bio-K+ CL1285 Bio-K+ International Improves digestive health; prevents
Antiobic Associated Diarrhea (AAD;
inhibition of pathogens
Lactobacillus acidophilus MNFLM01 &
Enterococcus faecium
LAB-MOS Alltech Lowers pathogen numbers in lamb
intestine
Lactobacillus helveticus R0052 &
Lactobacillus rhamnosus R0011
A’Biotica and others Institut Rosell Helicobacter pylori inhibition
For several other products with mixtures of probiotic bacteria see http://en.wikipedia.org/wiki/Probiotic#cite_note-48.
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used probiotics and the ones which have their genomes
sequenced are those associated with gut health. Details
of genomes sequenced before 2009 have been summa-
rized by Mayo and colleagues (2008) and Ventura and
colleagues (2009). Infants are born with a sterile gas-
trointestinal (GI) tract but in breast-fed babies coloniza-
tion by bifidobacteria is rapidly seen. It is thought that
these bacteria confer a health benefit to the infant. The
first colonizer is Bifidobacterium longum ssp. infantis,
which has the largest genome of any sequenced bifido-
bacteria at 2.83 Mb (Sela et al., 2008). The genome has
complete pathways for the synthesis of some vitamins
and a novel 43 kb gene cluster encoding a system for
the import and degradation of human milk oligosaccha-
rides (HMOs). After weaning, the numbers of this bifido-
bacterium decline but others become more dominant.
Bifidobacterium animalis ssp. lactis, a resident of the GI
tract and the most commonly used probiotic in Europe
and North America, has a genome size of only 1.9 Mb.
These bifidobacteria lack the HMO cluster as presum-
ably post-weaned animals no longer require this func-
tionality. They do, however, contain the fos gene cluster
necessary to produce the enzymes to break down and
utilize health-promoting fructo-oligosaccharides, a well-
known prebiotic and bifidogenic factor.
Several new genome sequences of probiotics have
been released in 2009. Bifidobacterium animalis ssp.
lactis AD011, isolated from a healthy breast-fed infant, has
a high level of immunomodulatory activity (Kim et al.,
2008b). Its genome encodes multiple glycosylases than
can degrade plant- or milk-derived oligosaccharides,
and the fos gene cluster for processing of fructo-
oligosaccharides (Kim et al., 2009). Bifidobacterium ani-
malis ssp. lactis strains B1-04 and DSM10140, both from
commercial probiotic products, differ only by 47 single
nucleotide polymorphisms and four small indels, of which
one indel in a CRISPR (Barrangou et al., 2009). Lactoba-
cillus johnsonii FI9785 is a competitive exclusion agent
against pathogens in poultry (Wegmann et al., 2009). Lac-
tobacillus plantarum JDM1 is a widely used Chinese com-
mercial probiotic strain which appears to have lost 100 kb
relative to the non-commercial strain WCFS1, encoding
sugar transport and metabolism, possibly due to pro-
longed growth of this probiotic strain in rich medium
(Zhang et al., 2009). Lactobacillus rhamnosus GG and
Lactobacillus rhamnosus ATCC53103, probiotic strains
Table 2. Publicly available sequenced complete genomes of (putative) probiotic bacteria (adapted from the GOLD Database (http://
www.genomesonline.org; October 2009).
Species Strain Accession Isolation source Reference
ACTINOBACTERIA
Bifidobacterium adolescentis ATCC 15703 NC_008618 Human faeces Unpublished; Gifu University, Japan
Bifidobacterium animalis ssp. lactis AD011 NC_011835 Human infant faeces Kim et al. (2009)
Bifidobacterium animalis ssp. lactis ATCC SD5219 NC_012814 Human infant faeces Barrangou et al. (2009)
Bifidobacterium animalis ssp. lactis DSM 10140 NC_012815 Swiss yoghurt Barrangou et al. (2009)
Bifidobacterium breve UCC203 Leahy et al. (2005)
Bifidobacterium longum NCC2705 NC_004307 Human infant faeces Schell et al. (2002)
Bifidobacterium longum DJO10A NC_010816 Human adolescent faeces Lee et al. (2008)
Bifidobacterium longum ssp. infantis ATCC 15697 NC_011593 Human infant faeces Sela et al. (2008)
Propionibacterium freundenreichii ATCC9614 Swiss cheese Unpublished; INRA, Rennes, France
FIRMICUTES
Lactobacillus acidophilus NCFM NC_006814 Human intestine Altermann et al. (2005)
Lactobacillus casei ATCC 334 NC_008526 Emmental cheese Makarova et al. (2006)
Lactobacillus casei BL23 NC_010999 Unpublished; INRA, Jouy-en-Josas,
France
Lactobacillus delbrueckii ssp. bulgaricus ATCC BAA-365 NC_008529 French starter culture Makarova et al. (2006)
Lactobacillus delbrueckii ssp. bulgaricus ATCC 11842 NC_008054 Bulgarian yoghurt van de Guchte et al. (2006)
Lactobacillus fermentum IFO 3956 NC_010610 Japanese fermented plant Morita et al. (2008)
Lactobacillus gasseri ATCC 33323 NC_008530 Human intestine Makarova et al. (2006)
Lactobacillus helveticus DPC 4571 NC_010080 Swiss cheese Callanan et al. (2008)
Lactobacillus johnsonii NCC533 NC_005362 Human intestine Pridmore et al. (2004)
Lactobacillus johnsonii FI9785 FN298497 Poultry Wegmann et al. (2009)
Lactobacillus plantarum WCFS1 NC_004567 Human saliva Kleerebezem et al. (2003)
Lactobacillus plantarum JDM1 NC_012984 Zhang et al. (2009)
Lactobacillus reuteri F275, JCM1112 NC_010609 Human adult intestine Morita et al. (2008)
Lactobacillus rhamnosus GG NC_013198 Human faeces Kankainen et al. (2009)
Lactobacillus rhamnosus ATCC53103 AP011548 Human intestine Morita et al. (2009)
Lactobacillus salivarius UCC118 NC_007929 Human small intestine Claesson et al. (2006)
Leuconostoc citreum KM20 NC_010471 Korean fermented
vegetables
Kim et al. (2008a)
In the ‘Ongoing genome sequencing projects’ (http://www.genomesonline.org/gold.cgi?want=Bacterial+Ongoing+Genomes#) in the GOLD
database, another 45 Bifidobacterium and 98 Lactobacillus strains are listed; incomplete genome sequence data is already publicly available for
10 and 34 of these strains respectively. Although many are gut isolates, not all will represent probiotic strains.
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used widely for nearly 20 years in a variety of functional
foods, differ only by deletion of 5 kb in ATCC53103, and
an inversion of 8.9 kb (Kankainen et al., 2009; Morita
et al., 2009). Compared with other sequenced intestinal
lactobacilli, both Lb. rhamnosus genomes have a rela-
tively high number of proteins involved in carbohydrate
and amino acid metabolism and transport, and defence
mechanisms. In particular, 28 complete PTS-type trans-
porters and 25 putative GHs are encoded, including the
alpha-L-fucosidase (GH29; see Cazy database http://
www.cazy.org) and alpha-mannosidase (GH38) families,
which are not found in other sequenced lactobacilli. In
addition, these Lb. rhamnosus genomes have three gene
clusters encoding proteins with WxL domains which can
attach to the peptidoglycan on cell surfaces (Siezen et al.,
2006; Brinster et al., 2007); again, these gene clusters
have not been found in other intestinal lactobacilli, but
rather in plant-associated Gram-positive bacteria (Siezen
et al., 2006). Most novel is the finding that Lb. rhamnosus
GG has a gene cluster spaCBA, encoding three secreted
pilin proteins with LPxTG-type peptidoglycan anchors,
which is not present in the highly syntenous genome of
Lb. rhamnosus LC705 (Kankainen et al., 2009). SpaA is
the major scaffolding protein upon which the minor pili
proteins SpaB and SpaC are attached. Using insertional
inactivation of spaC, a truncated SpaC protein was pro-
duced which resulted in cells with a greatly reduced
binding to human mucus (Kankainen et al., 2009). The
authors suggest that the presence of SpaC-containing pili
(Fig. 2) may possibly explain the longer persistence of this
0.01
L. paraplantarum
L. plantarum
L. pentosus
L.
 s
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riu
s
L. ruminis
L. equi
L. agilis L. manihotivorans
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L. acidophilus group
Fig. 1. Evolutionary relationships between the main gastrointestinal tract commensal lactobacilli, based on a neighbour-joining tree of 16S
rRNA gene sequences. Bootstrap values above 600 are indicated. Bacterial taxa for which whole genome sequences are available are shaded
in green. The outgroup is shaded in grey. Lactobacilli for which genome sequencing is ongoing/incomplete are shaded in red. Reproduced and
adapted from Ventura and colleagues (2009), with permission from Macmillan Publishers Limited, 2009.
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strain in the GI tract than strain LC705. Together with the
high potential for sugar uptake and metabolism, this may
explain probiotic effects of these Lb. rhamnosus strains.
Experimental omics exploration of
molecular mechanisms
Ingested probiotic microbes themselves will react to the
new environment of the intestine and change their gene
expression accordingly. Transcriptional responses of
bifidobacteria to human and formula milk have been
described in in vitro and in vivo experiments, the latter
from faecal samples of infants (Gonzalez et al., 2008;
Klaassens et al., 2009). Carbohydrate metabolism genes
are commonly upregulated, and include enzymes for deg-
radation of complex plant carbohydrates, which are poorly
digested by the host or other intestinal microbes (Klaas-
sens et al., 2009), and for metabolism of mucin and
HMOs (Gonzalez et al., 2008). In addition, putative genes
were upregulated for cell-surface type 2 glycoprotein-
Table 3. Proprietary genome sequences of commercial (putative) probiotic bacteria.
Species Strain
Genome
size (Mb) Company Reference
ACTINOBACTERIA
Bifidobacterium animalis ssp. lactis BB-12 2.0 Chr. Hansen, Denmark christel.garrigues@dk.chr-hansen.com
Bifidobacterium breve Yakult 2.35 Yakult, Japan yukio-shirasawa@yakult.co.jp
Bifidobacterium breve M-16V 2.3 Morinaga Milk, Japan k_nanba@morinagamilk.co.jp
Bifidobacterium longum biot infantis M-63 2.8 Morinaga Milk, Japan k_nanba@morinagamilk.co.jp
Bifidobacterium longum BB536 2.5 Morinaga Milk, Japan k_nanba@morinagamilk.co.jp
Bifidobacterium lactis 1.94 Danone, France tamara.smokvina@danone.com
FIRMICUTES
Lactobacillus brevis KB290 2.49 Kagome, Japan masanori_fukao@kagome.co.jp
Lactobacillus casei Shirota 3.03 Yakult, Japan yukio-shirasawa@yakult.co.jp
Lactobacillus casei 3.14 Danone, France tamara.smokvina@danone.com
Lactobacillus reuteri ATCC55730 2.0 SLU, Sweden klara.bath@mikrob.slu.se
Source: Abstracts Symposium on Lactic Acid Bacteria 2005 and 2008, Egmond aan Zee, the Netherlands.
©2009 by National Academy of Sciences
Fig. 2. Identification of pili in L. rhamnosus GG by immunogold high-resolution electron micrography. Multiple pili are shown with gold-labelled
SpaC proteins. Reproduced with permission from Kankainen and colleagues (2009).
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binding fimbriae that are implicated in attachment and
colonization in the intestine (Gonzalez et al., 2008).
In vitro transcriptional response of Lactobacillus reuteri
ATCC55730, a strain marketed for probiotic usage, to bile
stress has been described (Whitehead et al., 2008).
Upregulation was seen for genes involved in multidrug
transport, membrane/cell wall stress, oxidative stress,
DNA damage and protein denaturation. Transcription and
comparative genomics analysis of Lb. johnsonii NCC533,
an isolate characterized by long gut persistence, identified
three genetic loci that were specifically expressed in the
jejunum of mice mono-colonized with this strain, encoding
a PTS-type sugar transporter, glycosyltransferases and an
IgA-type protease (Denou et al., 2008). Several years ago,
a very elegant resolvase-based in vivo expression technol-
ogy was developed to study specific in vivo gene expres-
sion in L. plantarum WCFS1, using the mouse GI tract as a
model system (Bron et al., 2004). This has now been
followed up by whole genome transcriptome profiling of
strain WCFS1 during colonization of the caeca of germ-
free mice fed either standard low-fat rodent diet rich in
complex plant polysaccharides or a Western diet rich in
simple sugars and fats (Marco et al., 2009). Numerous
carbon metabolism pathways of L. plantarum were upregu-
lated on both diets, including uptake and utilization of
raffinose, cellulose, maltose, lactose/galactose, sucrose,
melibiose, sugar alcohols and sialic acid. Sialic acid is a
common component of (human) gut glycoproteins.
Host responses to potential probiotics have recently
been described in intervention studies in healthy human
volunteers. Duodenal mucosa was sampled after
intraduodenal infusion (Troost et al., 2008) or oral inges-
tion (van Baarlen et al., 2009) of L. plantarum WCFS1.
The continuous perfusion study showed that after
prolonged exposure, mucosal cells switched to a more
proliferative phase with upregulation of genes involved in
lipid metabolism, cellular growth and development. Cell
death and immune responses were triggered, but cell-
death executing cells or inflammatory signals were not
expressed. In the second study, consumption of live
L. plantarum cells showed striking modulation of NF-kB-
dependent pathways in mucosal cells, and identified cel-
lular pathways that correlated with the establishment of
immune tolerance in healthy adults (van Baarlen et al.,
2009). Figure 3 summarizes some of the mechanistic
events underlying probiotic effects that are beginning to
be understood from these in vitro and in vivo studies.
Adaptation of probiotic strains
Bifidobacterium longum DJO10A, an intestinal isolate, was
shown to lose functionality by gene loss after prolonged
pure culture (Lee et al., 2008). It would appear that when
growing in the competitive environment of the colon the
cells retained some important functionalities predicted to
be involved in diverse traits pertinent to the human intesti-
nal environment, specifically oligosaccharide and polyol
utilization, arsenic resistance and bacteriocin production.
The targeted loss of genomic regions was experimentally
validated when growth of the intestinal B. longum in the
laboratory for 1000 generations resulted in two large dele-
tions, one in a bacteriocin-encoding region, analogous
to a predicted deletion event in the commercial strain
B. longum NCC2705 (O’Sullivan, 2008). This deletion
strain showed a significantly reduced competitive ability
against Clostridium difficile and Escherichia coli. The
deleted region was between two IS30 elements which
were experimentally demonstrated to be hyperactive
within the genome. Hence, deletion of genomic regions,
often facilitated by mobile elements, allows bifidobacteria
to adapt to fermentation environments in a very rapid
manner (two genome deletions per 1000 generations) and
the concomitant loss of possible competitive abilities in the
gut. This has implications for industry, because the claims
for the use of a probiotic need to be fully substantiated.
Future
One of the most remarkable probiotic discoveries was
made by the German Alfred Nissle in 1917 in World War
I. Life in the trenches was dangerous and not just from
the fighting. Disease was rife, especially enterocolitis
(inflammation of the small and large intestine) caused by
outbreaks of shigellosis. One soldier did not succumb to
the disease and Nissle isolated from his faeces a bac-
terium with which he successfully treated other soldiers.
Escherichia coli Nissle 1917 is still in use and is one of
the few examples of a non-LAB probiotic (Mutaflor)
(Table 1). At present, many of the commercial probiotic
strains originate from the intestine of healthy infants and
adults. Current research focuses on the determination of
the characteristics these bacteria use to survive and
compete successfully in the intestine, and with this
knowledge more effective probiotic strains can be iden-
tified. To speed up this search, numerous gut meta-
genomic sequencing efforts are ongoing world-wide
to identify potential new probiotic candidates (Gill et al.,
2006; Kurokawa et al., 2007). See also the Human Gut
Metagenome Initiative (http://www.international.inra.fr/
press/mapping_the_human_intestinal_metagenome) and
the Human Gut Microbiome Initiative (Gordon et al., 2006)
(http://genomeold.wustl.edu/hgm/HGM_frontpage.cgi).
Perhaps the future will bring us health-promoting drinks
containing mixtures of many probiotic strains, much like
the cocktails used these days for vaccination against
infectious diseases. And what will be the next hype?
Memory-enhancing drinks would definitely be a commer-
cial success on quiz night in the pub!
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